



L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:120662 CAPLUS Full-text
 DN 142:219315
 TI Preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors
 IN Biftu, Tesfaye; Liang, Gui-Bai; Feng, Danqing Dennis; Weber, Ann E.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011581	A2	20050210	WO 2004-US24052	20040727
	WO 2005011581	A3	20050428		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2003-491606P	P	20030731		
OS	MARPAT 142:219315				
GI					



AB Title compds. I [Ar = Ph substituted with one to five R₃; R₃ = H, halo, cyano, etc.; R₁ = H, (un)substituted alkyl, (CH₂)_naryl etc., wherein aryl is (un)substituted with one to five substituents independently selected from halo, cyano, hydroxy, etc.; R₄, R₆, R₁₀ = H, cyano, carboxy, etc.; R₈ = halo, hydroxy, R₄; R₅, R₇, R₁₁ = H, alkyl; further details on R₁, R₇ are given; R₉ = H, hydroxy, halo, etc. with the proviso that at least one of R₆, R₇, R₈ and R₉ is not hydrogen] and their pharmaceutically acceptable salts were prepared For example, acylation of (3R,7R)-3,7-dimethyl-1,4- diazepan-2-one with (3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5- trifluorophenyl)butanoic acid, e.g., prepared from (2S)-2,5-dihydro-3,6- dimethoxy-2-isopropylpyrazine in 4 steps, using iso-Bu chloroformate followed by treatment with HCl afforded compound II hydrochloride. Compds. I are claimed useful for the treatment of hyperglycemia, type 2 diabetes, etc. (no data).

IT 842103-62-2P 842103-63-3P 842103-64-4P


842103-65-5P 842103-66-6P 842103-67-7P
842103-68-8P 842103-69-9P 842103-70-2P
842103-71-3P 842103-72-4P 842103-73-5P
842103-74-6P 842103-75-7P 842103-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors for treatment of hyperglycemia, type 2 diabetes, etc.)

RN 842103-62-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,7-dimethyl-, monohydrochloride, (3R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-63-3 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2-pyridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 842103-64-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-7-[(2-fluorophenyl)methyl]hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-65-5 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-7-[(2-fluorophenyl)methyl]hexahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-66-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-67-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-68-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-69-9 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[(2-methylphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-70-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[[2-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-71-3 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, monohydrochloride, (3R,6S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-72-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, monohydrochloride, (3R,6R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-73-5 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-6-methyl-, monohydrochloride, (3R,6S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-74-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-6-methyl-, monohydrochloride, (3R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-75-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-6-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride, (3R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-76-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-6-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride, (3R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 842103-78-0 842103-79-1 842103-80-4
842104-13-6 842104-14-7 842104-15-8
842104-16-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors
for treatment of hyperglycemia, type 2 diabetes, etc.)

RN 842103-78-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-
trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-7-methyl-,
(3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842103-79-1 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-
trifluorophenyl)butyl]hexahydro-7-methyl-3-[(2-methylphenyl)methyl]-,
(3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842103-80-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-
trifluorophenyl)butyl]hexahydro-7-methyl-3-[[2-
(trifluoromethyl)phenyl]methyl]-, (3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-13-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,7-dimethyl-, (3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-14-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-15-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, (3R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 842104-16-9 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2,2,2-trifluoroethyl)-,

(3R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 842104-11-4P 842104-12-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors for treatment of hyperglycemia, type 2 diabetes, etc.)

RN 842104-11-4 CAPLUS

CN Carbamic acid, [(1R)-3-[(2R,5R)-hexahydro-2,5-dimethyl-3-oxo-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-12-5 CAPLUS

CN Carbamic acid, [(1R)-3-[(2R,6S)-hexahydro-2,6-dimethyl-3-oxo-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:368864 CAPLUS Full-text

DN 140:391494

TI Preparation of β -amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

IN Biftu, Tesfaye; Liang, Gui-Bai; Qian, Xiaoxia; Weber, Ann E.; Feng, Danqing Dennis

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 74 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037169	A2	20040506	WO 2003-US32222	20031014
	WO 2004037169	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2502269	AA	20040506	CA 2003-2502269	20031014
	EP 1556362	A2	20050727	EP 2003-796347	20031014
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003015381	A	20050823	BR 2003-15381	20031014
	US 2004254167	A1	20041216	US 2004-501059	20040709
	NO 2005002380	A	20050616	NO 2005-2380	20050513
PRAI	US 2002-419703P	P	20021018		
	WO 2003-US32222	W	20031014		
OS	MARPAT 140:391494				
GI					



AB The invention relates to diazepinone β -amino acid derivs. I [Ar is substituted phenyl; R1 is (un)substituted alkyl, (CH₂)₀₋₂-aryl, -heteroaryl, -heterocyclyl or -cycloalkyl; R4, R5 are H, cyano, carboxy, carbalkoxy, (un)substituted alkyl, (CH₂)₀₋₂-aryl, etc.; R6, R9 are H or alkyl] which are inhibitors of the dipeptidyl peptidase-IV enzyme (DP-IV inhibitors) and are useful in the treatment or prevention of diseases, e.g., type 2 diabetes, in which DP-IV enzyme is involved. Thus, diazepinone II was prepared by a multistep procedure in which intermediate Me N-(3-aminopropyl)-N-(tert-butoxycarbonyl)-

D-alaninate underwent Me₃Al-catalyzed cyclization to tert-Bu (2R)-hexahydro-2-methyl-3-oxo-1H-1,4-diazepine-1-carboxylate.


IT 685857-73-2P 685857-75-4P 685857-77-6P
 685857-79-8P 685857-81-2P 685857-83-4P
 685857-86-7P 685857-89-0P 685857-92-5P
 685857-94-7P 685857-96-9P 685857-98-1P
 685858-00-8P 685858-02-0P 685858-04-2P
 685858-06-4P 685858-08-6P 685858-10-0P
 685858-12-2P 685858-14-4P 685858-16-6P
 685858-18-8P 685858-20-2P 685858-22-4P
 685858-24-6P 685858-26-8P 685858-28-0P
 685858-30-4P 685858-32-6P 685858-34-8P
 685858-36-0P 685858-38-2P 685858-40-6P
 685858-42-8P 685858-44-0P 685858-46-2P
 685858-48-4P 685858-50-8P 685858-52-0P
 685858-54-2P 685858-56-4P 685858-58-6P
 685858-60-0P 685858-62-2P 685858-64-4P
 685858-66-6P 685858-68-8P 685858-70-2P
 685858-72-4P 685858-74-6P 685858-76-8P
 685858-78-0P 685858-80-4P 685858-82-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of diazepinone β -amino acid derivs. as dipeptidyl peptidase inhibitors for treatment or prevention of diabetes)

RN 685857-73-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-75-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-77-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-(phenylmethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-79-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-81-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-1-(1,1-dimethylethyl)hexahydro-3-methyl-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-83-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 685857-86-7 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(1-oxido-2-pyridinyl)methyl]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-85-6

CMF C21 H23 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 685857-89-0 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(1-oxido-3-pyridinyl)methyl]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-88-9

CMF C21 H23 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 685857-92-5 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(1H-pyrazol-1-ylmethyl)-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-91-4

CMF C19 H22 F3 N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 685857-94-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685857-96-9 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-(cyclopropylmethyl)hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685857-98-1 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-00-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]-1-ethylhexahydro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-02-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-1-cyclopropylhexahydro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-04-2 CAPLUS

CN 1H-1,4-Diazepine-1-acetic acid, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-06-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-(2-hydroxyethyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-08-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-10-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-12-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]-3-ethylhexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-14-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(hydroxymethyl)-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-16-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2-fluorophenyl)-1-oxobutyl]hexahydro-1-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-18-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(3,4-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-20-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-[(phenylmethoxy)methyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 685858-22-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-24-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-26-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(3,4-difluorophenyl)-1-oxobutyl]hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-28-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-30-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[3-(trifluoromethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-32-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-([3-(trifluoromethoxy)phenyl]methyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-34-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[[3,5-bis(trifluoromethyl)phenyl]methyl]hexahydro-1-methyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-36-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-38-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-40-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-chlorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-42-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-44-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,5-dimethylphenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-46-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-48-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-([1,1'-biphenyl]-2-ylmethyl)hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-50-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,5-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-52-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-54-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-56-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,3-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-58-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-60-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-1-propyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 685858-62-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-64-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-1-methyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 685858-66-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-

trifluorophenyl)butyl]hexahydro-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-68-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,6-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-70-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-72-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-74-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-(phenylmethyl)-, (3R)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 685858-76-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-78-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-1-(1,1-dimethylethyl)hexahydro-3-methyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-80-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-82-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
 AN 137:159332 MARPAT Full-text
 TI Hypoglycemic agents comprising organic zinc(II) complexes
 IN Kojima, Yoshitane; Sakurai, Hiroshi; Yoshikawa, Yutaka
 PA Japan Science and Technology Corporation, Japan
 SO PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060432	A1	20020808	WO 2002-JP549	20020125
	W: CA, CN, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	JP 2003040784	A2	20030213	JP 2001-373289	20011206
	CA 2436425	AA	20020808	CA 2002-2436425	20020125
	EP 1364647	A1	20031126	EP 2002-716383	20020125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	CN 1536994	A	20041013	CN 2002-804391	20020125
	US 2004077620	A1	20040422	US 2003-470786	20030729
	US 2005130880	A1	20050616	US 2005-47206	20050128
PRAI	JP 2001-24532		20010131		
	JP 2001-373289		20011206		
	WO 2002-JP549		20020125		

AB Disclosed is a zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, α - and β - hydroxycarboxylic acids, vitamins, glutamine derivs., etc. L-Lactic acid zinc (II) complex was prepared, and its effect on blood glucose content in a diabetic mouse was examined Also, a soft cookie containing the obtained L-lactic acid/zinc (II) complex was prepared

MSTR 5



G2 = alkyl (opt. substd. by 1 or more G5)
 G5 = NH2 / 43




G7 = (1-3) CH2

Patent location:

claim 1

```
=> d l1; d his; log y
L1 HAS NO ANSWERS
L1          STR
```



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 18:13:04 ON 21 FEB 2006)

FILE 'REGISTRY' ENTERED AT 18:13:16 ON 21 FEB 2006

```
L1          STRUCTURE UPLOADED
L2          QUE L1
L3          6 S L1
L4          93 S L1 FUL
```

FILE 'CAPLUS' ENTERED AT 18:14:03 ON 21 FEB 2006

```
L5          2 S L4
```

FILE 'BEILSTEIN' ENTERED AT 18:14:36 ON 21 FEB 2006

```
L6          0 S L1
L7          0 S L1 FUL
```

FILE 'MARPAT' ENTERED AT 18:14:55 ON 21 FEB 2006

```
L8          0 S L1
L9          3 S L1 FUL
L10         1 S L9 NOT L5
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	122.17	300.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.71	-2.21

STN INTERNATIONAL LOGOFF AT 18:15:43 ON 21 FEB 2006